Sandra Talbird | Executive Director Health Economics & Modeling
RTI International, Health Solutions
Sandra Talbird designs and programs decision-analytic economic models, including cost-effectiveness, cost-utility, cost-benefit, and budget-impact models using Excel and Visual Basic for Applications. She has also developed mathematical models including compartmental dynamic transmission models for infectious diseases and linear programs in various software packages. She has experience generating real-world evidence for economic models through retrospective analyses of patient registry data, medical chart review studies, and clinical trial data. Ms. Talbird also has extensive experience in preparing economic submissions to health technology assessment agencies and National Immunization Technical Advisory Groups in many countries.
Ms. Talbird’s primary research focus is in infectious disease and vaccines, including treatment and prevention strategies for COVID-19, Ebola virus disease, HIV, acute and chronic hepatitis B, hepatitis C, seasonal influenza, invasive meningococcal disease, P. vivax and P. falciparum malaria, pertussis, pneumococcal disease, respiratory syncytial virus, tetanus, tuberculosis, and varicella zoster virus. Ms. Talbird is an active member of ISPOR. Her research has been presented at various professional conferences and published in several peer-reviewed journals, including AIDS, HIV Medicine, Pediatrics, Pharmacoeconomics, American Journal of Preventative Medicine, Value in Health, and Vaccine
Appearances:
Day 2 - World Orphan Drug Congress USA 2026 @ 10:30
Keynote Presentation: Revealing the Value of Cell & Gene Therapies: The Power of Disease Modeling
Small patient populations, limited natural history data, and uncertainty around long-term outcomes make value demonstration in rare diseases inherently challenging. These challenges affect all stakeholders—patients, providers, payers, and innovators—and require a more integrated approach. Disease modeling provides an objective, evidence-based framework to connect data, insights, and perspectives across the product life cycle, improving alignment and evidence generation.
We will present a gene therapy case study in sickle cell disease showing how disease modeling creates a clear throughline from early strategy to impactful evidence at launch.
Attendees across early development, market access, HEOR, and RWE will:
-See how early disease modeling drives key decisions across the product life cycle
-Identify where modeling unlocks value despite limited data
-Learn how to operationalize cross-stakeholder alignment, not just aspire to it
-Translate a single disease model into actionable evidence for multiple decision-makers
-Understand where modeling can, and should, be embedded in rare disease strategy
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events